Single peptide Vial strength 50 mg
Retatrutide50 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Retatrutide, explained simply
An investigational candidate that activates three metabolic receptors and is being studied in clinical weight management programmes.
Research area
Weight and metabolism
How it works
Retatrutide is an investigational agonist of the GLP-1, GIP, and glucagon receptors.
Why it matters
Clinical research examines weight management and other metabolic outcomes.
What has been observed
Phase 2 and phase 3 programs assess outcomes related to body weight and metabolism.
Effects and points to consider
Trial results depend on the population, product, and protocol studied; they do not validate vials from other sources.
01 / Vial strength 50 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 50 mg Retatrutide |
|---|---|
| Final volume | 2.5 mL |
| Concentration | 20 mg/mL |
| One U-100 unit | 200 mcg in 0.01 mL |
Phase 2 Trial Schedule (2.5 mL = 20 mg/mL)
| Study Phase | Weekly Dose | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2 mg | 10 units | 0.1 mL |
| Weeks 5 to 8 | 4 mg | 20 units | 0.2 mL |
| Weeks 9 to 12 | 8 mg | 40 units | 0.4 mL |
| Weeks 13+ | 12 mg | 60 units | 0.6 mL |
Phase 3 Trial Schedule (2.5 mL = 20 mg/mL)
| Study Phase | Weekly Dose | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2 mg | 10 units | 0.1 mL |
| Weeks 5 to 8 | 4 mg | 20 units | 0.2 mL |
| Weeks 9 to 12 | 6 mg | 30 units | 0.3 mL |
| Weeks 13 to 16 | 9 mg | 45 units | 0.45 mL |
| Weeks 17+ | 12 mg | 60 units | 0.6 mL |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.